Citius Pharmaceuticals, Inc. CTXR
Set alert
0.52 USD -0.04 -7.10%
At close · Oct 30
0.53 +0.01 +1.32%
After hours · Oct 30, 6:56 PM ET
0.5207 Day range 0.564
0.371 52-week range 1.58
- YTD
- -32.68%
- 1 year
- -66.68%
- Open
- 0.564
- Prev close
- 0.5631
- Mkt cap
- 14.36M
- Vol
- 104.67K
- Avg vol
- 474.58K
- EPS
- -1.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5207
- High
- 0.564
- Forward P/E
- 15.32
- Beta
- 1.66
- Short ratio
- 1.23
- Inst. own
- 13.17%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 3, 2025
- 50-d avg
- 6.51
- 200-d avg
- 14.50
- 1y target
- 54.00
Key statistics
- Market cap
- 22.49M
- Enterprise value
- 452.90M
- Trailing P/E
- 0.00
- Forward P/E
- 15.32
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.14
- EPS (TTM)
- -6.00
- Beta
- 1.66
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -16.83M
- Total cash
- 17.91M
- Total debt
- 320.01K
- Return on equity
- -41.49%
- Shares outstanding
- 7.73M
- Short % of float
- 8.34%
- 50-day average
- 6.51
- 200-day average
- 14.50
Analyst view
Consensus: none
Price target (mean) 54.00 +10223.1% upside
Now 0.5231
- Target (low)
- 8.00
- Target (mean)
- 54.00
- Target (high)
- 100.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy2
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Jan 3, 2025
Expected Jan 3, 2025. Consensus EPS estimate -1.50.
Financials — quick view
CTXR Revenue — quarterly 1.49M
CTXR Net income — quarterly -8.86M
CTXR EPS — quarterly -0.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 3, 2025 | Sep 1, 2024 | -2.00 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -1.25 | -1.50 | -0.25 | -20.00% |
| May 14, 2024 | Mar 1, 2024 | -1.50 | -1.25 | +0.25 | +16.67% |
| Feb 14, 2024 | Dec 1, 2023 | 3.25 | -1.50 | -4.75 | -146.15% |
| Dec 29, 2023 | Sep 1, 2023 | 0.00 | -1.75 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -1.50 | -1.50 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 22, 2024 | D. Boral Capital | down | Buy | Hold |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 11, 2024 | D. Boral Capital | main | Buy | Buy |
| Aug 19, 2024 | EF Hutton | main | Buy | Buy |
| Aug 8, 2024 | EF Hutton | main | Buy | Buy |
| Aug 5, 2024 | EF Hutton | main | Buy | Buy |
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- citiuspharma.com
News
- Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
- Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
- Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
- Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Now Rated “Hold” by Wall Street Brokerages
- Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis
- Brokerages Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) PT at $5.00
- Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate
Your note
Sign in to keep a note on CTXR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HOLUKA EUGENE MYRON | Director | Conversion of Exercise of derivative security | Mar 12, 2024 | 2,367 |
| WEBB CAROL A | Director | Conversion of Exercise of derivative security | Mar 3, 2024 | 11,835 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 1.57% | 291,040 | 846.93K | Sep 29, 2024 |
| Vanguard Group Inc | 1.39% | 257,633 | 749.71K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.41% | 75,158 | 218.71K | Sep 29, 2024 |
| Blackrock Inc. | 0.39% | 72,229 | 210.19K | Sep 29, 2024 |
| Millennium Management Llc | 0.25% | 46,340 | 134.85K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.20% | 37,273 | 108.46K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.89% | 165,584 | 481.85K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.42% | 78,316 | 227.90K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.21% | 37,994 | 110.56K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 11,688 | 34.01K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 8,990 | 26.16K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 9,090 | 26.45K | Oct 30, 2024 |